JB Pharma reports 35 percent increase in PAT at Rs 142 crore in Q1
New Delhi: JB Chemicals & Pharmaceuticals Ltd on Wednesday reported a 35 per cent increase in profit after tax at Rs 142 crore in the first quarter ended June 30, 2023. The company had posted a Profit After Tax (PAT) of Rs 105 crore in the same quarter last fiscal, JB Chemicals & Pharmaceuticals (JB Pharma) said in a statement.
Revenue in the quarter under review stood at Rs 896 crore as against Rs 785 crore in the year-ago period, a growth of 14 per cent, it added.
Established in 1976, J.B. Pharma, is one of the fastest-growing pharmaceutical companies in India and a leading player in the hypertension segment. Besides its strong India presence, which accounts for majority of its revenue, its other two home markets are Russia and South Africa. In India, the company has six brands among the top 300 IPM brands in the country. The company exports its finished formulations to over 40 countries including the USA. Besides supplying branded generic formulations to several countries, it is also a leader in the manufacturing of medicated lozenges. The company ranks among the top 5 manufacturers globally in medicated and herbal lozenges. It has seven state-of-the-art manufacturing facilities in India including a dedicated manufacturing facility for lozenges. The manufacturing facilities are certified by leading regulators across the world.
